2023 HFSA CME Symposium - Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Best Practices for Successful Outcomes in Patients with Heart Failure

HAZLET, N.J. - PrZen -- In this program, experts in cardiac amyloidosis will discuss best practices for identifying HF patients for screening for ATTR-CM, explain screening and diagnostic approaches, and describe current and emerging treatments for ATTR-CM.

Click here for more information

CHAIR

Mathew Maurer, MD
Professor of Medicine
Columbia University Medical Center
New York, New York

FACULTY

Ahmad Masri, MD, MS
Assistant Professor of Medicine
Oregon Health & Science University
Portland, Oregon

Brett Sperry, MD
Associate Professor of Medicine
University of Missouri-Kansas City
Kansas City, Missouri

This educational activity is intended for clinicians treating patients with heart failure.

Voxmedia LLC gratefully acknowledges the educational grant provided by AstraZeneca Pharmaceuticals.

Voxmedia LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This educational activity is approved for continuing nursing education (CNE) units by the HFSA, an accredited provider of the American Nurses Credentialing Center. This activity is approved for a maximum of 1.0 contact hours. Learners should claim only the credit commensurate with the extent of their participation in the activity.

The Heart Failure Society of America is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education (CPE). This activity is accredited for 1.0 contact hours of knowledge-based CPE under the ACPE universal activity number JA4008267-0000-21-003-L04-P.

Pre-registration is for planning purposes only and does not guarantee seating. For additional CME/CE activities visit www.CMEPlanet.com #HFSA2023 #ATTRCM #heartfailure #heart